US 12,357,576 B2
Formulations of triphenyl calcilytic compounds
Uma Sinha, San Francisco, CA (US); Ananth Sridhar, San Francisco, CA (US); Leena Prasad, San Francisco, CA (US); and Ali Komeyli, San Francisco, CA (US)
Assigned to CALCILYTIX THERAPEUTICS, INC., Palo Alto, CA (US)
Filed by CALCILYTIX THERAPEUTICS, INC., Palo Alto, CA (US)
Filed on Jun. 29, 2023, as Appl. No. 18/216,536.
Application 18/216,536 is a continuation of application No. 17/392,720, filed on Aug. 3, 2021, abandoned.
Claims priority of provisional application 63/061,050, filed on Aug. 4, 2020.
Prior Publication US 2024/0074978 A1, Mar. 7, 2024
Int. Cl. A61K 9/20 (2006.01); A61K 9/28 (2006.01); A61K 31/195 (2006.01)
CPC A61K 9/2018 (2013.01) [A61K 9/2009 (2013.01); A61K 9/2054 (2013.01); A61K 9/2853 (2013.01); A61K 31/195 (2013.01)] 11 Claims
 
1. A tablet formulation comprising:
a compound represented by formula (I):

OG Complex Work Unit Chemistry
a solvate, a hydrate, or a pharmaceutically acceptable salt thereof, or a combination thereof;
mannitol and microcrystalline cellulose in a combined amount of from about 50% to about 70% by weight of the tablet formulation;
colloidal silicon dioxide in an amount of from about 1% to about 4% by weight of the tablet formulation;
croscarmellose sodium in an amount of from about 10% to about 30% by weight of the tablet formulation;
hydroxypropyl methylcellulose in an amount of from about 2% to about 5% by weight of the tablet formulation; and
magnesium stearate in an amount of from about 1% to about 2% by weight of the tablet formulation.